Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma Clinical Trial

Official title:

An Observational Clinical Study on the Safety and Efficacy of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03692767
• Other study ID #: CD22 CAR NK-BJZL-01
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: March 2019
• Est. completion date: November 2021

Study information

• Verified date: September 2018
• Source: Allife Medical Science and Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9
• Est. completion date: November 2021
• Est. primary completion date: November 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. CD19 (+) B cell lymphoma confirmed by pathological immunohistochemistry or flow cytometry

2. Previously accepted = first-line regimen chemotherapy

3. Unconditional acceptance of hematopoietic stem cell transplantation or recurrence after hematopoietic stem cell transplantation

4. Over 18 years old and under 70 years old

5. The expected survival period is more than 3 months.

6. ECOG=2

7. Important organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction =50%, no abnormal electrocardiogram; blood oxygen saturation =90%; creatinine clearance =40 mL/min; ALT and AST=3 times normal range, Total bilirubin = 2.0 mg / dL;

8. Blood routine: Hgb=80 g/L, ANC=1×109/L, PLT=50×109/L;

9. The pregnancy test for women of childbearing age must be negative; both men and women must agree to use effective contraception during the treatment period and for the following 1 year.

10. Measurable target lesion

Exclusion Criteria:

1. Patients with extra-medullary relapse

2. Burkitt's lymphoma/leukemia

3. Previously received gene product treatment, anti-CD19/anti-CD3 treatment, or any anti-CD19 treatment;

4. Liver and kidney function:

Total bilirubin > 2 × ULN (Gilbert Syndrome > 3 × ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × ULN Serum creatinine clearance >60 mL/min

5. Serological examination:

Absolute neutrophil count (ANC) <0.75×109/L Platelet count (PLT) <50×109/L

6. Active hepatitis B (HBV-DNA > 1000 copies / mL), hepatitis C, or uncontrolled infection

7. GVHD = 2 or anti-GVHD treatment

8. IM19 CAR NK cells received allogeneic cell therapy within 6 weeks before infusion, such as donor lymphocyte infusion;

9. Subject received the most recent treatment (release, chemotherapy, or other) less than 4 weeks

10. Active CNS disease (tumor cells in CSF, but < 5 WBCs/mL can be included);

11. Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation

12. Creatinine > 1.5 times normal upper limit or ALT / AST > 3 times normal upper limit or bilirubin > 2 times normal upper limit

13. New York Heart Association (NYHA) graded above or above

14. Uncontrollable diabetes

15. Suffering from other uncontrolled diseases, the researchers believe that it is not suitable for joining

16. Any situation that the investigator believes may increase the risk of the subject or interfere with the test results

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Refractory B-Cell Lymphoma

Intervention

Biological:
• Anti-CD22 CAR NK Cells
Anti-CD22 CAR NK Cells injection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Allife Medical Science and Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment	Day 3-Year 2 after injection